Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Saniona

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from Boehringer Ingelheim

Contact the Supplier

Lead Product(s): SAN711

Therapeutic Area: Neurology Product Name: SAN711

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination November 05, 2020

Details:

The termination of the GABAa5 program provides Saniona with rights to a portfolio of more than 800 molecules; the company intends to evaluate their applicability in rare diseases.